Peer Reviewed
Case studies

A patient with familial hypercholesterolaemia unable to achieve target LDL-cholesterol levels

Leon A Simons
Abstract
Without treatment, a man with heterozygous familial hypercholesterolaemia has a 51% chance of presenting with coronary disease by age 50 years and a woman has a 58% chance by age 60 years.
Key Points
  • Patients with heterozygous familial hypercholesterolaemia (FH) have a high risk of manifesting with premature coronary disease.
  • Treatment with statins (and other standard cardiovascular medications) is likely to be beneficial.
  • Multiple lipid-regulating drugs may not achieve target LDL-cholesterol readings in patients with FH, but a 50% reduction in LDL-cholesterol levels is acknowledged as an acceptable secondary goal.
Get full access
Subscribe for full access to all articles
Buy this article

Single article purchases are temporarily unavailable due to site maintenance.

If you would like to purchase an article during this time, please email us at [email protected] with the article details and we'll assist you directly. We'll also let you know when online purchasing is available again.

Thank you for your patience and understanding.

Already a subscriber?